Performance of cell‐free DNA testing for common fetal trisomies in triplet pregnancies
Prenatal Diagnosis · 2024
DOI: 10.1002/pd.6548 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prenatal Diagnosis, 2024. Verfasst von Hoda Zakaria und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Obstetrics and Gynecology, "Antoine Béclère" Hospital, Paris Saclay University, APHP, Clamart, France. Hauptthemen laut MEDLINE: Cell-Free Nucleic Acids, Pregnancy, Triplet. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
In singleton pregnancies, the use of cell‐free DNA (cfDNA) analysis as a screening test for common fetal trisomies has spread worldwide though we still lack sufficient data for its use in triplet pregnancies. The objective of this study is to assess the performance of cfDNA testing in detecting fetal aneuploidies in triplet pregnancies as a first‐tier test.
Method
We performed a retrospective cohort study including data from pregnant women with a triplet pregnancy who underwent cfDNA testing between May 1, 2017, and January 15, 2020. cfDNA was obtained by massive parallel sequencing (VeriSeq NIPT solution; Illumina®). The objectives of the study were to assess the diagnostic performance of cfDNA testing for trisomy 21 (T21) (primary outcome), trisomy 18 (T18) and 13 (secondary outcomes).
Results
During the study period, cfDNA testing was performed in 255 women with triplet pregnancy, of which 165 (64.7%) had a neonatal outcome available. Three tests were positive for T21, one of which was confirmed by an antenatal karyotype, and the other was confirmed at birth. The third case did not undergo an invasive procedure and was not confirmed at birth (false positive). In one case, cfDNA testing was positive for T18 and was confirmed by an antenatal karyotype. There were no cases of trisomy 13 in the cohort. The no‐call rate was 2.4% at first sampling. Fifty‐eight (22.7%) women had embryo reduction, which in 40 (69%) of whom was performed after the cfDNA test result. Conclusion cfDNA testing could be offered as primary screening for main fetal aneuploidies in triplet pregnancies after provision of appropriate patient information.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Obstetrics and Gynecology, "Antoine Béclère" Hospital, Paris Saclay University, APHP, Clamart, France.
- Laboratoire Cerba, Saint-Ouen l'Aumône, France.
- Division of Obstetrics and Gynecology, "Port Royal" Hospital, Paris Cité University, APHP, Paris, France.
- Division of Obstetrics and Gynecology, "Necker-Enfants Malades" Hospital, Paris Cité University, APHP, Paris, France.
- Division of Fetal Medicine, "Armand Trousseau" Hospital, Sorbonne Paris Nord University, APHP, Paris, France.
- Division of Obstetrics and Gynecology, "Robert Debré" Hospital, Sorbonne Paris Nord University, APHP, Paris, France.
ORCID-Profile: Laurent J Salomon, Jean-Marie Jouannic, Jonathan Rosenblatt, Alexandra Benachi
Zitieren
APA
Zakaria, H., Kleinfinger, P., Lohmann, L., Costa, J. M., Tsatsaris, V., Salomon, L. J., Jouannic, J. M., Rosenblatt, J., Demain, A., Benachi, A., El Khattabi, L., & Vivanti, A. J. (2024). Performance of cell‐free DNA testing for common fetal trisomies in triplet pregnancies. Prenatal Diagnosis. https://doi.org/10.1002/pd.6548
Vancouver
Zakaria H, Kleinfinger P, Lohmann L, Costa JM, Tsatsaris V, Salomon LJ, et al. Performance of cell‐free DNA testing for common fetal trisomies in triplet pregnancies. Prenatal Diagnosis. 2024. doi:10.1002/pd.6548
BibTeX
@article{Zakaria2024,
author = {Zakaria, Hoda and Kleinfinger, Pascale and Lohmann, Laurence and Costa, Jean-Marc and Tsatsaris, Vassilis and Salomon, Laurent J and Jouannic, Jean-Marie and Rosenblatt, Jonathan and Demain, Adèle and Benachi, Alexandra and El Khattabi, Laïla and Vivanti, Alexandre J},
title = {Performance of cell‐free DNA testing for common fetal trisomies in triplet pregnancies},
journal = {Prenatal Diagnosis},
year = {2024},
doi = {10.1002/pd.6548}
}
EUVIMED